Skip to main content
Edwards Lifesciences Logo

Promising data. Inspiring results.

inspiring results
inspiring results
inspiring results

The Edwards Advantage

We are committed to providing your institution, clinicians and staff with the highest levels of customer service and support to ensure seamless product implementation and ongoing use, including:

Monday through Friday, 8:00am to 17:00pm CET


Contact a sales representative

If you would like further information about our privacy policy, please click here.

Would you like to opt-in to receive future email communications from Edwards Lifesciences?

This includes notification of future symposia, forums, conference activities, product updates, and educational events.


  1. Tod reference is: TJ Tod et al. Cardiovasc Eng Technol 2021;12:418-25.
  2. Flameng W, et al. J Thorac Cardiovasc Surg. 2015;149:340–5.
  3. Bartus K et al. Eur J Cardiothorac Surg 2021;59:434-41.
  4. Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2023 Sep 29:S0022-5223(23)00873-5.Epub ahead of print. PMID: 37778503.
  5. Pibarot P, et al. Structural Heart. 2020;4(1):46-52.

Medical device for professional use

No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients

Medical device for professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult  where applicable).